Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA To Draw Up 'Critical Medicine' Lists For Future Health Crises

Industry Will Be ‘Invited’ To Review Product Lists

Executive Summary

As part of its expanded mandate, the EU regulator is identifying those medicines whose supply will need to be closely monitored during health crisis situations. The lists will draw on various information sources, including real-world evidence databases.

You may also be interested in...



Coronavirus Notebook: Global COVID-19 Summit To Press For More Funding For Vaccines & Treatments, WHO Calls For End To IP Waiver ‘Stalemate’

CEPI has announced funding for a “variant-proof” vaccine being developed by a multidisciplinary consortium. The European Medicines Agency's new committee on drug shortages in health crises has held its first meeting, and the European Parliament’s new COVID-19 committee will quiz the health commissioner on the EU’s vaccines strategy and response to the pandemic.

EU Health Data Project: More Use Of Real-World Evidence In Price Negotiations

The proposed European Health Data Space is expected to boost innovation in preventing, diagnosing and treating disease and to support the long-term competitiveness of the EU’s medical sector. The pharmaceutical industry has broadly welcomed the move but wants to see certain safeguards and guarantees put in place.

New Zealand To Overhaul Ageing Regulatory System

Drug approvals, clinical trials, pharmacovigilance and the use of unauthorized drugs are among areas targeted by draft legislation on a new therapeutic products scheme.

Topics

UsernamePublicRestriction

Register

PS146165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel